All In MedTech

FDA Clearance Tracker · P970007

IMX TACROLIMUS II ASSAY

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Aug 26, 1997 (this decision)Source: openFDAMethods & limitations

PMAFirst of its product code

Decided

Aug 26, 1997

Approved (reclassified)

Time to decision

189 days

Received Feb 18, 1997. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class II

The decision

FDA number
P970007
Device name
IMX TACROLIMUS II ASSAY
Applicant location
Abbott Park, IL
Received
Feb 18, 1997
Decided
Aug 26, 1997
Decision
Approved (reclassified)
Expedited review
Yes, flagged as expedited in FDA's record.
Supplements
4 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class II
Regulation
21 CFR 862.1678

Every decision under product code MLM

FDA's approval statement

As written in FDA's record.

Approval for the IMx(R) Tacrolimus II Assay. This device is indicated for use as an in-vitro reagent sytemf or the quantitative determination of tacrolimus and some metabolites in human whole blood as an aid in the management of liver allograft patients receiving tacrolimus therapy.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • This is the earliest decision in FDA's data under product code MLM (ENZYME IMMUNOASSAY, TRACROLIMUS).
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Abbott Laboratories

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.